MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
ARCA biopharma EV/EBITDA Ratio 2011-2026 | ABIO
Annual EV/EBITDA Ratio ARCA biopharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.84 | 2.08 | 0.245 | 0.0635 | -0.549 | -0.965 | 1.31 | 0.0824 | -0.0727 | -1.44 | -0.591 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 | -1.44 | 0.182 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
13.7 | $ 7.71 | 1.65 % | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
-1.66 | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-15.7 | $ 221.52 | -0.16 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Heron Therapeutics
HRTX
|
-4.31 | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M |  Israel |
 |
Immunovant
IMVT
|
918 | $ 24.27 | 5.61 % | $ 3.68 B | USA |
 |
Incyte Corporation
INCY
|
24 | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
14.6 | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
INmune Bio
INMB
|
-3.64 | $ 1.23 | 5.13 % | $ 22.1 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-2.19 | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-6.65 | $ 1.34 | 14.26 % | $ 235 M | France |
 |
Calithera Biosciences
CALA
|
-7.96 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-6.7 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
0.0235 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-0.833 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-3.86 | - | -7.23 % | $ 13 M | USA |
 |
Inventiva S.A.
IVA
|
-9.77 | $ 6.09 | 5.36 % | $ 138 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
-7.07 | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
-3.44 | $ 16.93 | -0.41 % | $ 841 M | Britain |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
-3.52 | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-3.41 | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
-386 | $ 8.33 | 0.97 % | $ 260 M | Israel |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |